Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13527222 | 0.99 | MIF (0.56) | MIFBCHECA12CA1CA2 | |
| SCHEMBL16479596 | 0.89 | MIF (0.60) | MIFBCHECA12CA1CA2 | |
| SCHEMBL17795660 | 0.88 | MIF (0.59) | MIFBCHECA12CA1CA2 | |
| SCHEMBL13527010 | 0.88 | CA12 (0.44) | MIFBCHECA12CA1CA2 | |
| SCHEMBL15060892 | 0.82 | MIF (0.62) | MIFBCHECA12CA1CA2 | |
| SCHEMBL15060865 | 0.82 | MIF (0.66) | MIFBCHECA12CA1CA2 | |
| SCHEMBL13527307 | 0.81 | MIF (0.64) | MIFBCHECA12CA1CA2 | |
| SCHEMBL15060983 | 0.81 | MIF (0.68) | MIFBCHECA12CA1CA2 | |
| SCHEMBL13527252 | 0.81 | MIF (0.60) | MIFBCHECA12CA1CA2 | |
| SCHEMBL15060974 | 0.80 | MIF (0.71) | MIFBCHECA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349621-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2017-12-07 | — | — | US | disclosed |
| US-9085600-B2 | Triazole compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140094422-A1 | Triazole Compounds and Methods of Making and Using the Same | SILICON VALLEY BANK | 2014-04-03 | — | — | US | disclosed |
| US-8470985-B2 | Triazole compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349621-A1 | TRIAZOLE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PROKR1, ARG1, ARG2 | MIF 196/4885BCHE 2005/4885CA12 4447/4885 |
| US-20140094422-A1 | Triazole Compounds and Methods of Making and Using the Same | PROKR1, ARG1, ARG2 | MIF 196/4885BCHE 2005/4885CA12 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.